Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Cholangiocarcinoma is a type of cancer that forms in the slender tubes (bile ducts) that carry the digestive fluid bile. The specific reason for the cause of cholangiocarcinoma is not known as of yet. The malignant tumor may arise from any portion of the bile duct i.e., from terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural) and may sometimes affect gall bladder as well. The significant symptoms of cholangiocarcinoma includes jaundice, weight reduction, loss of hunger, blood in stool and urine, stomach pain, fever, and itching.
The global cholangiocarcinoma market is estimated to be valued at US$ 185.4 million in 2021 and is expected to exhibit a CAGR of 12.8 % during the forecast period (2021-2028).
Figure 1.Global Cholangiocarcinoma Market Share (%) in Terms of Value, By Treatment Type, 2021
Increasing prevalence of cholangiocarcinoma is expected to drive the market growth during the forecast period.
Increasing prevalence of cholangiocarcinoma is expected to drive the global cholangiocarcinoma market growth over the forecast period. For instance, according to American Cancer Society’s 2018 report, around 8,000 people in the U.S. are diagnosed with cholangiocarcinoma to each year. This includes both intrahepatic (inside the liver) and extrahepatic (outside the liver) bile duct cancers.
Figure 2.Global Cholangiocarcinoma Market Share (%), By Distribution Channel, 2021
Key players operating in the global cholangiocarcinoma market are focusing on adoption of inorganic growth strategies such as acquisition which are expected to drive the market growth during the forecast period.
key companies are focusing on inorganic strategies such as acquisition in order to strengthen their products presence and this is expected to create a conductive environment for growth of the Cholangiocarcinoma market. For instance, in January 2021, Servier, a global pharmaceutical company, announced the acquisition of Agios Pharmaceuticals company’s commercial, clinical, and research-stage oncology portfolio which includes Tibsovo (ivosidenib tablets) for treatment of Cholangiocarcinoma and others.
Cholangiocarcinoma Market Report Coverage
||Market Size in 2021:
||US$ 185.4 Mn
|Historical Data for:
||2017 to 2020
||2020 to 2027
|Forecast Period 2021 to 2028 CAGR:
||2027 Value Projection:
||US$ $ 429.6 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Treatment Type:
- Chemotherapy: Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine, 5 fluorouracil (5-FU)
- Targeted Therapy: Pemigatinib, Infigratinib (Phase 3), Ivosidenib (Phase 3)
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc.
- Increasing Prevalence of Cholangiocarcinoma
- Increasing Drug Approvals and Launches
|Restraints & Challenges:
- High Cost of Cholangiocarcinoma and Cancer Treatment
- Time-consuming Approach to Approving New Drugs
Global Cholangiocarcinoma Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread over 100 countries across the globe and the World Health Organization had declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 143 million infected individuals worldwide as of April 21st 2021.
COVID-19 affects the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs. For instance, In April 2020, Chinese suppliers stopped supplies to India due to non-availability of labour, containers are piling up and all space is occupied. The incoming vessels will not be able to offload the containers and may bypass that result in the shortage of medicines in India.
Furthermore, players operating in the global cholangiocarcinoma market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges includes supply of raw materials (due to irregularities in transportation), which are required for manufacturing drug formulations. Moreover, distributors are experiencing irregular demand for products from the retailers due to an increase in the number of patients suffering from COVID-19 and other life threatening disorders.
Global Cholangiocarcinoma Market: Restraint
The major factors that hinder growth of the global cholangiocarcinoma market includes high cost of cholangiocarcinoma and cancer treatments and the time-consuming approach for approving new drugs.
Major players operating in the global cholangiocarcinoma market are Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc.